Regeneron PharmaceuticalsREGN
REGN
About: Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Employees: 14,176
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 16 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
57% more first-time investments, than exits
New positions opened: 137 | Existing positions closed: 87
17% more repeat investments, than reductions
Existing positions increased: 529 | Existing positions reduced: 453
4% more funds holding
Funds holding: 1,309 [Q2] → 1,359 (+50) [Q3]
4% less capital invested
Capital invested by funds: $100B [Q2] → $96B (-$4.21B) [Q3]
2.7% less ownership
Funds ownership: 87.99% [Q2] → 85.29% (-2.7%) [Q3]
18% less funds holding in top 10
Funds holding in top 10: 28 [Q2] → 23 (-5) [Q3]
22% less call options, than puts
Call options by funds: $1.41B | Put options by funds: $1.8B
Research analyst outlook
16 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$165
76%
downside
Avg. target
$1,014
44%
upside
High target
$1,215
73%
upside
16 analyst ratings
11 positive
69%
4 neutral
25%
1 negative
6%
Canaccord Genuity John Newman 48% 1-year accuracy 13 / 27 met price target | 76%downside $165 | Hold Initiated | 17 Dec 2024 |
B of A Securities Tim Anderson 50% 1-year accuracy 3 / 6 met price target | 20%downside $565 | Underperform Reinstated | 10 Dec 2024 |
Wolfe Research Alexandria Hammond 33% 1-year accuracy 3 / 9 met price target | 64%upside $1,150 | Outperform Initiated | 15 Nov 2024 |
Citigroup Geoff Meacham 28% 1-year accuracy 7 / 25 met price target | 28%upside $895 | Neutral Initiated | 14 Nov 2024 |
Oppenheimer Hartaj Singh 29% 1-year accuracy 8 / 28 met price target | 42%upside $1,000 | Outperform Maintained | 6 Nov 2024 |
Financial journalist opinion
Based on 25 articles about REGN published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Regeneron to Advance Two Factor XI Antibodies into a Broad Phase 3 Program Following Positive Phase 2 Proof-of-concept Results
Investigational REGN7508 (catalytic domain) and REGN9933 (A2 domain) are being evaluated for their potential to control thrombosis while minimizing bleeding risk in a variety of patient populations and clinical settings
Positive
Zacks Investment Research
3 days ago
REGN's Eylea HD Shows Non-Inferiority to Eylea in Eye Disease Study
Regeneron's phase III study evaluating Eylea HD against stand-of-care Eylea treatment meets the primary endpoint of non-inferior visual gain in RVO patients.
Neutral
GlobeNewsWire
4 days ago
Regeneron Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
TARRYTOWN, N.Y., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast its presentation at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation is scheduled for 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time) and may be accessed from the "Investors & Media" page of Regeneron's website at http://investor.regeneron.com/events-and-presentations.com/events-and-presentations. A replay and transcript of the webcast will be archived on the Company's website for at least 30 days.
Neutral
GlobeNewsWire
5 days ago
Regeneron Named to Dow Jones Sustainability World Index for Sixth Consecutive Year
TARRYTOWN, N.Y., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced its sixth consecutive inclusion in the Dow Jones Sustainability World Index (DJSI World) and fifth consecutive inclusion in the Dow Jones Sustainability North America Index (DJSI North America). These rankings highlight the company's leadership in adopting responsible practices that drive business resilience and improve our world.
Neutral
Zacks Investment Research
1 week ago
Regeneron Down 15.5% Year to Date: How to Play the Stock?
REGN's lead drug, Eylea, faces a rapid decline in sales, which has impacted overall performance, even though Dupixent maintains momentum. We advise investors to wait and watch for now.
Neutral
Schaeffers Research
1 week ago
Biotech Roundup: 3 Stocks to Watch
Most recently in the ever-growing biotech industry , investors are musing over potential changes to the sector after President-elect Donald Trump picked Martin “Marty” Makary to be the U.S. Food and Drug Administration's (FDA) next commissioner, and Robert F.
Neutral
Accesswire
1 week ago
Lost Money on Regeneron Pharmaceuticals, Inc.(REGN)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky
NEW YORK, NY / ACCESSWIRE / December 10, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ:REGN) concerning possible violations of federal securities laws. On October 31, 2024, Regeneron released its third quarter 2024 financial results, reporting "U.S. net sales for EYLEA HD® and EYLEA® increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HD.
Neutral
GlobeNewsWire
1 week ago
Odronextamab ASH Presentations Underscore Impressive Potential in Earlier Lines of Treatment and Additional Types of Lymphoma
Odronextamab monotherapy led to complete responses in all patients with previously untreated follicular lymphoma evaluable for efficacy, per initial results from the safety lead-in portion of the confirmatory Phase 3 OLYMPIA-1 trial
Neutral
Accesswire
1 week ago
Regeneron Pharmaceuticals, Inc. Being Investigated on Behalf of Regeneron Pharmaceuticals, Inc. Investors. Contact Levi & Korsinsky For Details.
NEW YORK, NY / ACCESSWIRE / December 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Regeneron Pharmaceuticals, Inc. ("Regeneron Pharmaceuticals, Inc.") (NASDAQ:REGN) concerning possible violations of federal securities laws. On October 31, 2024, Regeneron released its third quarter 2024 financial results, reporting "U.S. net sales for EYLEA HD® and EYLEA® increased 3% versus third quarter 2023 to $1.54 billion, including $392 million from EYLEA HD.
Neutral
GlobeNewsWire
2 weeks ago
Novel Combination of Pozelimab and Cemdisiran (Poze-Cemdi) Achieved Greater Control of Intravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Compared to Ravulizumab
Head-to-head exploratory cohort of a Phase 3 trial showed first-in-class poze-cemdi combination treatment helped patients achieve and maintain greater disease control, as measured by lactate dehydrogenase (LDH) levels, compared to standard-of-care ravulizumab
Charts implemented using Lightweight Charts™